SUMOylation is a dynamic process, catalyzed by SUMO-specific ligases and reversed by Sentrin/SUMO-specific proteases (SENPs). The physiologic consequences of SUMOylation and deSUMOylation are not fully understood. Here we investigate the phenotypes of mice lacking SENP1 and find that SENP1 À/À embryos show severe fetal anemia stemming from deficient erythropoietin (Epo) production and die midgestation. We determine that SENP1 controls Epo production by regulating the stability of hypoxia-inducible factor 1a (HIF1a) during hypoxia. Hypoxia induces SUMOylation of HIF1a, which promotes its binding to a ubiquitin ligase, von Hippel-Lindau (VHL) protein, through a proline hydroxylation-independent mechanism, leading to its ubiquitination and degradation. In SENP1 À/À MEFs, hypoxia-induced transcription of HIF1a-dependent genes such as vascular endothelial growth factor (VEGF) and glucose transporter 1 (Glut-1) is markedly reduced. These results show that SENP1 plays a key role in the regulation of the hypoxic response through regulation of HIF1a stability and that SUMOylation can serve as a direct signal for ubiquitin-dependent degradation.
INTRODUCTION
Conjugation of small ubiquitin-related modifier protein (SUMO) to a large number of substrates has been suggested to regulate numerous cellular processes from yeast to mammal (Hay, 2005; Yeh et al., 2000) . Most SUMO targets are in the nucleus; they include transcription factors, transcriptional coregulators, and chromosome-remodeling regulators (Gill, 2004) . SUMOylation of these proteins can alter their cellular localization and biological activity.
SUMO conjugation is a dynamic process, in that it can be readily reversed by a family of Sentrin/SUMO-specific proteases (SENPs) (Hay, 2005; Yeh et al., 2000) . Six SENPs have been identified in human, each with different cellular location and substrate specificity . They can be divided into three subfamilies on the basis of their sequence homology, cellular location, and substrate specificity. The first subfamily consists of SENP1 and SENP2, which have broad substrate specificity. The second subfamily consists of SENP3 and SENP5, both of which are nucleolar proteins with preferences for SUMO-2/3 (Di Bacco et al., 2006; Gong and Yeh, 2006) . The third subfamily consists of SENP6 and SENP7, which have an extra loop in their catalytic domains. Although SENPs are known to reverse SUMOylation in many different systems, their physiological role has not been precisely defined.
SENP1, a nuclear SUMO protease, has been shown to regulate androgen receptor transactivation by targeting histone deacetylase 1 and to induce c-Jun activity through deSUMOylation of p300 (Cheng et al., 2004 (Cheng et al., , 2005 . Yamaguchi et al. studied mice derived from an ES cell line with a retroviral vector that had been randomly inserted into the enhancer region on the SENP1 gene. This random insertion reduced expression of the SENP1 transcript, causing the mice to die between E12.5 and E14.5 (Yamaguchi et al., 2005) . Although no specific histological abnormalities were found in the E13.5 embryos, there was a hint of an abnormality in the development of blood vessels in the placenta. Thus, it remains unclear how SENP1 contributes to normal development.
Therefore, we generated SENP1 knockout mice to delineate the contribution of SENP1 in development. Inactivation of the SENP1 gene causes severe fetal anemia in midgestation as a result of deficient Epo production. Epo is essential for growth and survival of erythroid progenitors during differentiation into red cells (Wu et al., 1995) . We found that SENP1 controls Epo production by regulating the stability of hypoxia-inducible factor 1a (HIF1a). Hypoxia induces HIF1a SUMOylation, which promotes HIF1a degradation through a VHL-and proteasome-dependent mechanism. SENP1 deconjugates SUMOylated HIF1a and allows HIF1a to escape degradation during hypoxia. These results reveal an important physiological role of SENP1 in the hypoxic response through regulation of HIF1a stability and that SUMOylation can also target a protein for ubiquitination and degradation.
RESULTS

Generation of SENP1 Knockout Mice
To generate SENP1 knockout mice, a gene-trapped vector was inserted into the mouse SENP1 open reading frame at codon 310 ( Figure S1A ). Specifically, the inserted b-geo (b-galactosidase/neomycin-resistance fusion protein) was fused into the N terminus of SENP1 at codon 310 to generate SENP1 (1-309)-b-geo fusion protein, which lacks the C-terminal catalytic domain of SENP1 ( Figure S1A ). This disruption was confirmed by the absence of transcripts that encode the catalytic domain of SENP1 in SENP1 À/À embryos ( Figure S1B ). The overall SUMOylation pattern in lysates of embryos revealed an increase in high-molecular-weight SUMO-1 and SUMO-2/3 conjugates in SENP1 À/À embryos in comparison with wild-type or SENP1 +/À embryos ( Figure S1C ). In addition,
processing of the C terminus of SUMO-1 but not SUMO-2/ 3 appeared to be decreased in SENP1 À/À embryos ( Figure S1C ). These results indicate that disruption of the SENP1 locus reduced deSUMOylation in SENP1 À/À embryos.
Severe Anemia in SENP1 À/À Embryos Heterozygous mice carrying the inactivated SENP1 gene appeared normal and fertile. However, no live SENP1 À/À mice were found among offsprings of SENP1 +/À intercrosses, indicating that the SENP1 À/À mutation leads to embryonic lethality. Examination of SENP1 À/À embryos at different stages of development revealed that the majority died between days 13 and 15 of gestation ( Figure 1A ). The SENP1 À/À embryos appeared paler and smaller than their wild-type or SENP1 +/À littermates ( Figure 1B ). The most dramatic morphological abnormality of these SENP1 À/À embryos was severe fetal anemia. In particular,
SENP1
À/À embryos had more than 75% fewer erythrocytes than their wild-type or SENP1 +/À littermates at E15.5 ( Figure 1C ).
Defective Definitive Erythropoiesis in SENP1
À/À Embryos During normal murine development, erythropoiesis is initiated in the yolk sac at around E8 (primitive erythropoiesis), and then it is initiated in the aorta-gonadmesonephros (AGM) region. At midgestation, fetal liver becomes the major hematopoietic organ with hematopoietic activity starting around E11.0 to E12.5 until 1 week postnatal (definitive erythropoiesis) (Godin and Cumano, 2002) . Because anemia was observed after E13.5 in SENP1 À/À embryos, we reasoned that these embryos likely had a defect in definitive erythropoiesis. Indeed, the number of nucleated cells in the fetal livers of SENP1 À/À embryos was markedly decreased compared to their wild-type littermates ( Figure 1D ). Histological examination of fetal liver sections also revealed a marked decrease in the number of erythropoietic foci in SENP1 À/À embryos compared with their wild-type littermates ( Figure 1E ).
Increased Apoptosis in Erythroid Precursors of SENP1
À/À Embryos We next examined hematopoiesis in the fetal livers of both wild-type and SENP1 À/À embryos at E13.5 by flow cytometry using markers, including CD34, CD44, c-kit, and Ter-119, characteristic of different types of hematopoietic cells and developmental stages (Kondo et al., 2003; Neubauer et al., 1998) . There was no significant difference between SENP1 À/À embryos and wild-type littermates,
except that the population of Ter-119 + , which denotes committed erythropoietic precursors, was markedly reduced in SENP1 À/À fetal livers ( Figure S2A ). These data suggest that erythropoiesis was abnormal in SENP1
embryos as a result of a defect in erythroid differentiation.
To determine at which stage of erythroid differentiation SENP1 plays a crucial role, we compared the abilities of cells derived from wild-type and SENP1 À/À E13.5 fetal livers to form erythroid colony-forming units (CFU-e) and more immature erythroid burst-forming units (BFU-e) (Wu et al., 1995) . Although fetal livers from SENP1 À/À embryos contained erythroid progenitors, the relative number of CFU-e arising from SENP1 À/À fetal liver was over 40%
smaller than that from wild-type fetal liver ( Figure 2A ). However, there was no significant difference in the numbers of the BFU-e between SENP1 À/À and wild-type fetal livers ( Figure 2A ). Additionally, we observed no significant difference in the number of colony-forming unit granulocyte-macrophage (CFU-GM) and pluripotent hematopoietic stem cells (CFU-GEMM) between SENP1 À/À and wild-type fetal livers ( Figure S2B ). These results indicate that a developmental defect in CFU-e is a prominent feature in the SENP1 À/À embryo.
The reduced ratio of CFU-e to BFU-e progenitors and the decrease in the number of Ter-119 + erythroid cell suggested a reduction in the net growth of SENP1 À/À erythroid progenitors resulting from either decreased cell proliferation or increased apoptosis. No differences were observed in the proliferation of fetal liver cells between SENP1 À/À embryos and their wild-type littermates, as shown by Ki-67 staining (upper panel, Figure S2C ). However, TUNEL staining showed that the number of TUNEL-positive cells was much greater in the liver sections from SENP1 À/À embryos than in those of their wild-type littermates (lower panel, Figure S2C ). Figure 2B ). These results suggested that the erythroid cells in fetal liver were more apoptotic in SENP1 À/À embryos than in their wild-type counterparts, which accounts for the decrease in CFU-e progenitors, smaller fetal liver size, and anemia in SENP1 À/À embryos.
Epo Production Is Reduced in SENP1
À/À
Fetal Liver
The hematopoietic defect in SENP1 À/À embryos described above was similar to that observed in Epo À/À embryos or in embryos with mutation of the genes critical to the Epo signaling pathway (Neubauer et al., 1998; Parganas et al., 1998; Socolovsky et al., 1999; Wu et al., 1995) . Since fetal liver erythroid progenitors depend on Epo for growth and survival during terminal differentiation into red blood cells (Wu et al., 1995) , we reasoned that the increased apoptosis of erythroid cells in SENP1 À/À fetal liver could be due to either a defect in Epo production or blockage in the Epo signaling pathway. To assess these possibilities, we first examined the expression of genes involved in the Epo signaling pathway (specifically, EpoR, Jak2, and STAT5) and other growth factors associated with erythroid progenitors in fetal livers. A dramatic reduction in the level of Epo mRNA expression was shown in SENP1 À/À fetal livers ( Figure 2C ). In contrast, the expression of EpoR, Jak2, STAT5, and growth factors c-kit and SCF was not significantly different between SENP1
À/À and wild-type fetal livers ( Figure 2C ). The reduced Epo expression in E12.5 fetal liver cells of SENP1 À/À embryos was further confirmed by immunohistochemistry (Figure 2D ). These results demonstrated that Epo production was significantly reduced in SENP1 À/À fetal livers.
Epo Prevents Apoptosis of SENP1
Fetal Liver Cells
To determine whether apoptosis of cells in the fetal livers of SENP1 À/À embryos was caused by a deficiency in Epo production, we examined the ability of Epo to prevent apoptosis of the erythroid progenitors from SENP1 À/À fetal liver. As shown by rates of apoptosis in vitro, E13.5 wild-type fetal liver cells, which were grown in a medium lacking Epo, showed a reduction in cell number and increase in apoptosis similar to those observed in fetal liver cells of their SENP1 À/À littermates. Addition of Epo to the culture medium prevented reduction in cell number and apoptosis in SENP1 À/À fetal liver cells similar to their wild-type littermates ( Figures 2E and 2F ). These results demonstrated that the increased apoptosis of erythroid progenitors was due to deficiency in Epo production in SENP1 À/À fetal liver.
SENP1 Regulates Epo Transcription through HIF1a
The Epo gene is expressed primarily in fetal liver and adult kidney and is regulated in response to oxygen availability (Ebert and Bunn, 1999) . Since SENP1 is expressed in mouse fetal liver at midgestation stage ( Figure S3 ), we reasoned that SENP1 might directly regulate Epo expression in fetal liver. A hepatoma cell line, Hep 3B, was used to determine whether SENP1 regulated Epo production. Two SENP1-specific siRNAs were able to efficiently knock down SENP1 expression ( Figure S4 ) and significantly reduced Epo expression in Hep 3B cells in response to treatment with hypoxia ( Figure 3A ), indicating that SENP1 played an important role in Epo production under the hypoxia condition. Since SENP1 regulates the transcription of numerous genes by targeting transcription factors or coregulators (Cheng et al., 2004 (Cheng et al., , 2005 , we next examined whether Epo transcription was also regulated by SENP1. In this study, the luciferase reporter gene driven by the Epo promoter plus enhancer (Epo-Luc) was transfected into Hep 3B cells with SENP1 or SENP1 catalytic inactive mutant (SENP1m), in which a conserved amino acid, cysteine 603, in the catalytic domain of SENP1 was substituted with alanine. In the presence of hypoxia, SENP1, but not the SENP1 mutant, significantly induced Epo reporter gene transcription ( Figure 3B ), suggesting that SENP1 regulated Epo transcription and the regulation required the deSUMOylation activity of SENP1. Interestingly, without hypoxia treatment, SENP1 had only marginal effect on Epo transcription.
Since HIF1a is a major transcription factor for hypoxiaregulated Epo expression , we asked whether HIF1a was required for SENP1-regulated Epo transcription. Coexpression of SENP1 markedly enhanced HIF1a-dependent Epo transcription ( Figure 3C ). However, mutation of HIF1a-binding sites on the Epo enhancer (mEpo-Luc) completely abolished SENP1 activity (Figure 3C ). Furthermore, silencing of endogenous SENP1 expression in Hep 3B cells using SENP1 siRNA (SENP1-si1 and SENP1-si2) also reduced Epo transcription in response to HIF1a by 80% ( Figure 3D ). These results strongly suggested that Epo expression was regulated by SENP1 through its regulation of HIF1a activity.
SENP1 Is Essential for Ensuring HIF1a Stability during Hypoxia
It is well-known that regulation of HIF1a occurs mostly at the protein level. In SENP1 À/À mice, HIF1a protein level was significantly decreased in a section of the SENP1 À/À fetal liver compared with the SENP1 +/+ littermate ( Figure 4A ). However, HIF1a mRNA levels in fetal livers of SENP1 À/À or wild-type embryos were similar, suggesting that the decrease in HIF1a protein level resulted from protein degradation but not a reduction of HIF1a transcription in SENP1 À/À embryos ( Figure S5 ).
HIF1a is degraded by a proteasome-dependent mechanism under normoxia (Huang et al., 1998; Maxwell et al., 1999; Wang et al., 1995) . Hypoxia was believed to stabilize HIF1a protein and therefore increased its activity Huang et al., 1998; Maxwell et al., 1999) . We hypothesized that regulation of HIF1a protein to hypoxia was defective in SENP1 À/À cells. To test this possibility, we determined changes in HIF1a protein level in SENP1 À/À and wild-type MEF cells when exposed to hypoxia. As shown in Figure 4B , hypoxia markedly increased the protein level of HIF1a in the wild-type MEF cells, but the increase was much less in the SENP1 À/À MEF cells.
Furthermore, the half-life of HIF1a protein was markedly reduced in the SENP1 À/À MEF cells under the hypoxia condition in a pulse-chase experiment ( Figure 4C ). Normoxia-induced HIF1a degradation is dependent on its internal oxygen-depend-degradation (ODD) domain (Huang et al., 1998) . We then determined whether the ODD domain was a direct target of SENP1 regulation of HIF1a stability under hypoxia condition. We used the HIF1a ODD domain (344-698) fused Gal4 (pG4-ODD-VP16), which was previously demonstrated to have normoxic-and VHL-dependent degradation and activity (Huang et al., 1998; Maxwell et al., 1999) . Indeed, coexpression of SENP1 markedly enhanced hypoxia-induced ODD activity. However, hypoxia-induced activity of the ODD domain was completely abolished by SENP1-siRNA ( Figure 4D ). These results strongly indicated that SENP1 was essential for HIF1a stabilization under hypoxia condition. Consistent with the decrease in HIF1a expression during hypoxia, HIF1a activity was also significantly reduced in SENP1 À/À MEF cells as measured by the response of the HRE-luciferase reporter gene to hypoxia in SENP1 À/À and wild-type MEF cells ( Figure 4E ). As HIF1a is a major transcription factor in the regulation of a large number of hypoxia-inducible genes, we also showed that hypoxia-induced transcription of VEGF and Glut-1 genes was dramatically decreased in SENP1 À/À MEF cells ( Figure 4F ). This defect was similar to the response of HIF1a À/À ES upon hypoxia exposure (Iyer et al., 1998; Ryan et al., 1998) . We further confirmed that this defect in SENP1 À/À MEF cells was mediated by HIF1a, as transfected HIF1aSM (SUMOylation mutant) could restore hypoxia-induced expression of the VEGF gene in the transfected cells ( Figure 4G ). These results indicated that SENP1 S6 ). The effect of deSUMOylation on HIF1a activity was directly confirmed by using HIF1a SUMOylated site mutants: K391R, K477R, and K391/477R (SM) (Bae et al., 2004) . As shown in Figure 5B , mutation of the two SUMOylation sites of HIF1a (SM) significantly increased the transcriptional activity of HIF1a and also reduced the ability of SENP1 to enhance HIF1a-dependent Epo transcription. Furthermore, hypoxia-induced accumulation of SUMOylated HIF1a only occurred in SENP1 À/À MEF cells but not in wild-type cells ( Figure 5C ). Interestingly, this accumulation did not appear in SENP2 À/À MEF cells ( Figure S7 ), suggesting that SENP1 specifically targeted HIF1a for deSUMOylation ( Figure 5C ).
The simultaneous accumulation of SUMOylated HIF1a and the decrease in HIF1a stability in SENP1 À/À cells during hypoxia prompted us to study whether SUMOylation might lead to HIF1a degradation. Indeed, SUMOylated bands of HIF1a resulted from coexpression of HIF1a and HA-SUMO-1 and were difficult to detect in the absence of a proteasome inhibitor MG132 but readily detectable when both SENP1 siRNA and MG132 were used ( Figure 5D ). These results were further confirmed by examining endogenous HIF1a in SENP1 HIF1a was degraded in a proteasome-dependent manner during hypoxia in the absence of SENP1.
Degradation of SUMOylated HIF1a Is Dependent on VHL
The above results suggest that SUMO and SENP1 might regulate ubiquitination of HIF1a. As shown in Figure 6A , ubiquitination of HIF1a was significantly increased when SUMO-1 was overexpressed (lane 3 versus lane 2 in Figure 6A ). In contrast, cotransfection of SENP1, but not SENP1 mutant, significantly decreased ubiquitination of HIF1a (lanes 4 and 5 versus 2 in Figure 6A ). We asked whether VHL, a well-known E3 ligase for HIF1a ubiquitination (Ivan et al., 2001; Jaakkola et al., 2001; Maxwell et al., 1999; Ohh et al., 2000) , could also serve as an E3 ligase for SUMOylated HIF1a. To address this possibility, we first examined hypoxia-induced SUMOylation of HIF1a in RCC4 (renal cancer cells with inactivated VHL) and RCC4/VHL (VHL-restored RCC4 cells) (Maxwell et al., 1999) . SUMOylated HIF1a was easily detected in VHL null RCC4 cells even without MG132 treatment (lane 2 versus 3 in top panel, Figure 6B ). In contrast, this band was only weakly detectable in RCC4/VHL cells exposed to hypoxia and MG132 treatment. Consistent with other reports, hypoxia-induced increase in HIF1a protein was only observed in VHL-restored RCC4 cells (bottom panel, Figure 6B ). These results suggested that SUMOylated HIF1a was degraded through a VHL-dependent mechanism.
SUMO Provides an Alternative Signal for HIF1a to Bind to VHL
We further speculated that SUMOylation serves as an alternative signal for HIF1a to bind to VHL during the hypoxic condition. The interaction of SUMOylated HIF1a and VHL in vivo was examined first by using a HIF1a proline residue 402/564 mutant (PM), which would decrease background binding that resulted from hydroxylation of HIF1a. As shown in Figure 6C , SUMOylation of HIF1a PM was greatly enhanced by expression of SENP1siRNA plus MG132 treatment (lane 4, bottom panel, Figure 6C ). SUMOylated HIF1a from the nuclear fraction was efficiently coprecipitated by VHL (lane 4 in top and second panels, Figure 6C ). To directly confirm the binding of VHL and SUMOylated HIF1a, we performed an in vitro binding assay. As shown in Figure 6D , VHL pulled down SUMOylated GST-ODD(344-698) PM, detected by anti-HIF1a antibody ( Figure 6D , middle panel). These bands were confirmed as SUMOylated HIF1a by anti-SUMO-1 antibody ( Figure 6D , right panel). Importantly, unmodified GST-ODD(344-698) PM, even though presented in a much larger quantity than SUMOylated GST-ODD(344-698) PM, could not be coprecipitated by VHL. We further mapped the SUMObinding domain on VHL protein by using recombinant SUMO-fused GST-ODD(344-698) PM to pull down in vitro-translated VHL deletion mutants. As shown in Figure 6E , SUMO-fused GST-ODDPM protein could pull down VHL deletion mutants that contained the b domain. However, SUMO-fused GST-ODDPM protein could not pull down the VHL deletion mutant that only contained the a domain. This was dependent on SUMO-1 because GST-ODDPM could not pull down any VHL deletion mutants. Interestingly, b domain is well documented as a substrate-binding region when VHL acts as a component of the E3 ligase complex (Ohh et al., 2000; Stebbins et al., 1999) . Taken together, these results clearly suggest that SUMOylation of HIF1a could serve as an alternate signal for binding to VHL in the absence of proline hydroxylation.
To directly demonstrate the role of SENP1 in VHL-dependent degradation of SUMOylated HIF1a, we generated SENP1 siRNA stably transfected RCC4 and RCC4/ VHL cell lines. The expression of endogenous SENP1 was significantly decreased in these two cell lines ( Figure S8 ). Silencing of SENP1 markedly decreased HIF1a expression in RCC4/VHL but not in RCC4 cells ( Figure 6F ), confirming that HIF1a turnover promoted by inactivation of SENP1 was VHL dependent.
DISCUSSION
Biological Consequence of SUMOylation and DeSUMOylation SUMOylation and deSUMOylation have been shown to regulate a large number of biological processes, including transcription, cell signaling, cell-cycle progression, and cancer pathogenesis (Cheng et al., 2006; Yeh et al., 2000) . However, many of these studies were carried out in cell culture systems overexpressing enzymes involved in SUMOylation and deSUMOylation. A limited number of studies have addressed the physiological importance of this emerging pathway of biological regulation. For example, knocking out the SUMO conjugation enzyme Ubc9 in mice resulted in embryonic lethality at the early post-implantation stage (Nacerddine et al., 2005) . Ubc9-deficient cells showed severe defects in nuclear organization including chromosome condensation and segregation. This study indicates that global disruption of the SUMOylation pathway is lethal in mammals. Consistent with this, mice with an incomplete SENP1 knockout die between E12.5 and E14.5 (Yamaguchi et al., 2005) .
In the present study, we show that SENP1 plays an essential role in the deconjugation of SUMOylated HIF1a. This deconjugation has important biological consequence as SENP1 À/À embryos are severely anemic, which is most likely the cause of fetal death. This is surprising because in an overexpression system, both SENP1 and SENP2 have identical substrate specificity. Here, SUMOylated HIF1a is only regulated by SENP1 but not SENP2 in vivo. Thus, SENPs clearly perform nonredundant biological functions in both MEF cells and animals.
Regulation of HIF1a Stability during Hypoxia
HIF1a is mainly regulated at the level of protein stability (Huang et al., 1998; Jiang et al., 1996) . During normoxia,
HIF1a is hydroxylated at two critical proline residues by a family of oxygen-sensitive enzymes, prolyl 4-hydroxylases (PHD) (Bruick and McKnight, 2001; Epstein et al., 2001; Yu et al., 2001 ). Proline-hydoxylated HIF1a then binds to VHL, a component of the ubiquitin E3 ligase complex that consists of Cul-2, VHL, elongin B, and elongin C (Bruick and McKnight, 2001; Ivan et al., 2001; Jaakkola et al., 2001; Maxwell et al., 1999) . Subsequently, HIF1a is ubiquitinated and degraded by the proteasome. It was assumed that during hypoxia, proline hydroxylation occurs inefficiently, thus allowing HIF1a to escape binding to VHL and proteasomal degradation (Figure 7) . Most studies about HIF1a stability primarily focus on the mechanism involving the regulation of PHD enzymatic activities (Epstein et al., 2001; Gerald et al., 2004; Ivan et al., 2001; Jaakkola et al., 2001; Nakayama et al., 2004) . However, a few reports have shown that there are other factors that can regulate HIF1a stability in a VHL-independent manner. For example, Liu et al. recently showed that RACK1 could replace HSP90's binding of HIF1a and target the unmodified HIF1a to the elongin C complex for ubiquitination and degradation (Liu et al., 2007) . There are also modifications other than hydroxylation that regulate HIF1a stability and activity (Brahimi-Horn et al., 2005) . Our SENP1 À/À embryos demonstrate that a SUMOylation and deSUMOylation cycle is involved in the regulation of HIF1a stability during hypoxia. Hypoxia induces nuclear translocation (Kallio et al., 1998) and, as we have shown here, SUMOylation of HIF1a, which binds to VHL in a hydroxyl proline-independent manner, leading to ubiquitination and proteasomal degradation (Figure 7 ). It should be noted that SUMOylation is not required for hypoxia-induced nuclear translocation of HIF1a (X.K. and E.T.H.Y., unpublished data). We currently do not know how hypoxia Hypoxia blocks the activity of PHD, preventing hydroxylation of HIF1a and its subsequent degradation in a VHL-and ubiquitin-dependent manner. On the other hand, hypoxia induces nuclear translocation and SUMOylation of HIF1a, which provides an alternative signal for VHL-and ubiquitin-dependent degradation. SENP1 stabilizes HIF1a by removing the alternative VHL-binding signal.
induces SUMOylation of HIF1a. This may be due to an increase in SUMO E3 ligase activity (X.K. and E.T.H.Y., unpublished data). SENP1, which is predominately a nuclear protein, is well positioned to regulate the stability of HIF1a in the nucleus by removing SUMO . Unmodified HIF1a would escape VHL/proteasomedependent degradation to participate in the regulation of hypoxia-responsive genes. When SENP1 is absent, SUMOylated HIF1a will be degraded through a VHL/proteasome-dependent mechanism ( Figure 6 ). Groulx et al. have proposed that HIF1a is degraded in the cytosol (Groulx and Lee, 2002) . However, we do not know whether SUMOylated and ubiquitinated HIF1a is also degraded in the cytosol. Further studies are required to resolve this issue. A previous study showed that overexpression of SUMO-1 increased HIF1a protein level and its activity not only under hypoxia but also in normoxia condition (Bae et al., 2004) , leading to the hypothesis that SUMOylation stabilizes HIF1a. This model is inconsistent with our results demonstrating that SUMOylation leads to the degradation of HIF1a. The contrasting results from the previous study may be attributed to the overexpression of SUMO-1 in the presence of SENP1. In the presence of SENP1, SUMOylated HIF1a will be deconjugated and indeed stabilized. The SENP1 knockout mouse has enabled us to uncover an opposite role for SUMOylation in the regulation of HIF1a.
SUMOylation Can Target a Protein for Proteasomal Degradation
Our results provide direct evidence that SUMOylation can induce degradation of a target protein in a proteasomedependent manner. It is well accepted that SUMOylation can stabilize target proteins, as SUMO can conjugate to the same lysine sites on target proteins as in ubiquitination (Hay, 2005) . Although ubiquitin-conjugated sites on the HIF1a protein have not been defined precisely, the reported ubiquitin-conjugated region of HIF1a indicates that at least lysines 391 and 477, two SUMOylation sites on the HIF1a protein, are not the major sites for ubiquitination (Ivan et al., 2001; Masson et al., 2001; Ohh et al., 2000) . We also found that the level of HIF1a SUMOylation correlated with the level of ubiquitination, suggesting that SUMO conjugation of HIF1a is not on the same sites as ubiquitination. More importantly, we identified an E3 ubiquitin ligase VHL for SUMOylated HIF1a degradation. It was previously shown that PML could be SUMOylated and ubiquitinated when exposed to arsenic trioxide (Lallemand-Breitenbach et al., 2001) . However, it is not known whether SUMOylated PML is required for binding to an ubiquitin ligase to allow for ubiquitination and degradation. Currently, we also do not know whether SUMO-mediated binding of substrates to ubiquitin E3 can be generalized to more SUMOylated substrates.
In conclusion, our results support a model in which SUMOylated HIF1a is unstable but can be stabilized when SUMO is removed by SENP1 (Figure 7) . When SENP1 is deleted, SUMOylated HIF1a is degraded, in a VHL-and ubiquitin/proteasome-dependent manner, resulting in decreased Epo production and severe fetal anemia. This study provides evidence for the physiological role of deSUMOylation as demonstrated in an animal model; our study also reveals that SUMOylation can target a protein for ubiquitination and proteasomal degradation.
EXPERIMENTAL PROCEDURES
Generation of SENP1
À/À Mice
The SENP1 +/À ES cell line XG001 was obtained from BayGenomics.
XG001 cells were generated by using a gene trap protocol with the trapping construct pGT1Lxf containing the intron from the engrailed-2 gene upstream of the gene encoding the b-galactosidase/neomycin-resistance fusion protein (see http://baygenomics.ucsf.edu). The vector was inserted into intron 8 of the SENP1 locus. A male chimeric mouse was generated from the ES cell line. C57 BL6 mice were obtained from The Jackson Laboratory.
Plasmids and Antibodies
The Epo enhancer (Epo-Luc) and the HIF1a-binding site mutant (mEpo-Luc) were provided by Dr. H.M. Sucov. HRE-Luc was provided by Dr. J. Yi. pGal4-VP16 and pGal4-ODD(344-698)-VP16 were provided by Dr. P.J. Ratcliffe. Flag-VHL was provided by Dr. T. Kamitani. VHL(1-213), VHL(54-213), VHL(63-155), and VHL(156-213) were provided by Dr. M. Ohh. HA-SUMO-1, Flag-SENP1, and Flag-SENP1 catalytic mutant were previously described (1, 2). RGS-HIF1a, RGSHIF1aK391R, RGS-HIF1aK477R, RGS-HIF1aSM (K391R, K477R), RGS-HIF1a PM (P402A, P564A), pET-ODD(344-698)PM(p402A, P564A), and pET-ODD(344-698)PM-SUMO1 were generated using standard cloning procedures and PCR-based mutagenesis. We used antibodies against Flag (M2, Sigma), HA (HA-7, Sigma), Myc (Santa Cruz), SUMO-1 (Zymed), SUMO-2/3 (gifted from Dr. Mike Matunis), mouse HIF1a (Novus), and human HIF1a (BD).
Histopathologic and Immunohistochemistry Analysis
Embryos were fixed in 10% buffered formalin (Sigma) and embedded in paraffin. Five-micrometer-thick sections were stained with hematoxylin and eosin. For proliferation studies, the sections were stained with Ki67-specific antibodies (Dako). Apoptotic cells were detected in sections using the TUNEL stain (TACS TdT DAB kit, R&D).
Colony-Formation Assays
Cells were prepared from the livers of E13.5 embryos in a-MEM (GIBCO-BRL) and counted in the presence of 3% acetic acid, which lysed erythrocytes. Cell suspensions were mixed with MethoCult M3334 to detect BFU-e or MethoCult M3434 to detect CFU-e (StemCell Technologies). Cells were plated in 35 mm dishes and cultured at 37 C in an atmosphere containing 5% CO 2 . For the CFU-e assay, benzidine-positive CFU-e colonies were scored on day 3. For the BFU-E assay, benzidine-positive BFU-e colonies were scored on day 8.
Flow Cytometry
Single-cell suspensions were obtained from E13.5 wild-type and mutant fetal livers. Cell suspensions were first incubated on ice with rat anti-mouse CD16/CD32 (PharMingen) to block nonspecific binding to Fc receptors. Subsequently, cells were incubated with rat antimouse PE-conjugated anti-c-kit and anti-CD44 and FITC-conjugated anti-CD34 and anti-Ter-119 (all from PharMingen). Appropriate isotype control antibodies were used. Cell-surface expression of different markers was analyzed in a Becton Dickinson FACScan using CellQuest software. For the TUNEL assay, cells were stained using a TUNEL kit from Roche and then analyzed by flow cytometry.
RNA Interference
Two 21 nucleotide SENP1 siRNAs (si-1: AACTACATCTTCGTG TACCTC; si-2: CTAAACCATCTGAATTGGCTC) were synthesized (Dharmacon). The same sequence of the si-1-inverted orientation was used as a nonspecific siRNA control. The SENP1 and nonspecific siRNA oligos were inserted into a pSuppressorNeo vector (IMGENEX Corporation) according to manufacturer's instructions. Hep 3B cells were transfected with the siRNA plasmid using lipofectamine 2000 (Invitrogen). RCC4 and RCC4/VHL (purchased from ECACC) were infected by retrovirus-based SENP1si-1 virus particles produced from pSuppressorNeo-SENP1si-1 and selected by G418. Silencing efficiency of the siRNA was confirmed by performing real-time PCR (for Hep 3B) or RT-PCR (for RCC4 and RCC4/VHL) to examine SENP1 expression. TaqMan Master Mix Reagents (Applied Biosystems) were utilized for quantitative real-time PCR (QRT-PCR) reaction. The TaqMan ABI PRISM 7000 Sequence Detector System (PE Applied Biosystems) was used for the analysis. Primers for SENP1 (forward: 5 0 -TTGGCCA GAGTGCAAATGG-3 0 ; reverse: 5 0 -TCGGCTGTTTCTTGA TTTTTGTAA-3 0 ) and the housekeeping 18S rRNA (ABI) were utilized.
In Vitro SUMOylation Assay
In vitro SUMOylation kit was purchased from LAE Biotech International (Rockville, MD). The reaction was carried out at 37 C for 1 hr with the mixture including E1 (150 ng), E2 (5 mg), SUMO-1 (5 mg), ATP (2 mM), and GST-ODD(344-698)PM (300 ng).
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